These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

680 related items for PubMed ID: 24050600

  • 1. Everolimus: a new hope for patients with breast cancer.
    Sendur MA, Zengin N, Aksoy S, Altundag K.
    Curr Med Res Opin; 2014 Jan; 30(1):75-87. PubMed ID: 24050600
    [Abstract] [Full Text] [Related]

  • 2. Everolimus and its role in hormone-resistant and trastuzumab-resistant metastatic breast cancer.
    Keck S, Glencer AC, Rugo HS.
    Future Oncol; 2012 Nov; 8(11):1383-96. PubMed ID: 23148612
    [Abstract] [Full Text] [Related]

  • 3. Everolimus: targeted therapy on the horizon for the treatment of breast cancer.
    Barnett CM.
    Pharmacotherapy; 2012 Apr; 32(4):383-96. PubMed ID: 22461124
    [Abstract] [Full Text] [Related]

  • 4. Evolving strategies for overcoming resistance to HER2-directed therapy: targeting the PI3K/Akt/mTOR pathway.
    Nahta R, O'Regan RM.
    Clin Breast Cancer; 2010 Nov; 10 Suppl 3():S72-8. PubMed ID: 21115425
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. A systematic review of dual targeting in HER2-positive breast cancer.
    Kümler I, Tuxen MK, Nielsen DL.
    Cancer Treat Rev; 2014 Mar; 40(2):259-70. PubMed ID: 24080156
    [Abstract] [Full Text] [Related]

  • 7. Phase I trial of oral mTOR inhibitor everolimus in combination with trastuzumab and vinorelbine in pre-treated patients with HER2-overexpressing metastatic breast cancer.
    Jerusalem G, Fasolo A, Dieras V, Cardoso F, Bergh J, Vittori L, Zhang Y, Massacesi C, Sahmoud T, Gianni L.
    Breast Cancer Res Treat; 2011 Jan; 125(2):447-55. PubMed ID: 21107682
    [Abstract] [Full Text] [Related]

  • 8. [The drug of the month: everolimus (Afinitor) for the treatment of metastatic breast cancer].
    Jerusalem G, Rorive A, Collignon J.
    Rev Med Liege; 2014 Sep; 69(9):510-7. PubMed ID: 25796760
    [Abstract] [Full Text] [Related]

  • 9. [Exemestane-everolimus in HER2-negative, hormonal receptor-positive, post-menopausal metastatic breast cancer with resistance to non-steroidal aromatase inhibitor: a new option].
    Gilabert M, Launay S, Gonçalves A.
    Bull Cancer; 2014 Mar; 101(3):325-33. PubMed ID: 24691195
    [Abstract] [Full Text] [Related]

  • 10. A phase II study of combined fulvestrant and everolimus in patients with metastatic estrogen receptor (ER)-positive breast cancer after aromatase inhibitor (AI) failure.
    Massarweh S, Romond E, Black EP, Van Meter E, Shelton B, Kadamyan-Melkumian V, Stevens M, Elledge R.
    Breast Cancer Res Treat; 2014 Jan; 143(2):325-32. PubMed ID: 24327334
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Phase I/II study of trastuzumab in combination with everolimus (RAD001) in patients with HER2-overexpressing metastatic breast cancer who progressed on trastuzumab-based therapy.
    Morrow PK, Wulf GM, Ensor J, Booser DJ, Moore JA, Flores PR, Xiong Y, Zhang S, Krop IE, Winer EP, Kindelberger DW, Coviello J, Sahin AA, Nuñez R, Hortobagyi GN, Yu D, Esteva FJ.
    J Clin Oncol; 2011 Aug 10; 29(23):3126-32. PubMed ID: 21730275
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Bone effects of mammalian target of rapamycin (mTOR) inhibition with everolimus.
    Hadji P, Coleman R, Gnant M.
    Crit Rev Oncol Hematol; 2013 Aug 10; 87(2):101-11. PubMed ID: 23838481
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. A Phase II Open Label Study of Everolimus in Combination With Endocrine Therapy in Resistant Hormone Receptor-Positive HER2-Negative Advanced Breast Cancer.
    Yardley DA, Liggett W, Mainwaring M, Castrellon A, Blakely L, Hemphill B, Anz B, Young RR, Shastry M, DeBusk LM, Hainsworth JD, Burris HA.
    Clin Breast Cancer; 2020 Apr 10; 20(2):89-97. PubMed ID: 31932237
    [Abstract] [Full Text] [Related]

  • 18. Pertuzumab in HER2-positive breast cancer.
    Sendur MA, Aksoy S, Altundag K.
    Curr Med Res Opin; 2012 Oct 10; 28(10):1709-16. PubMed ID: 22953713
    [Abstract] [Full Text] [Related]

  • 19. Targeted agents to reverse resistance to endocrine therapy in metastatic breast cancer: where are we now and where are we going?
    Fedele P, Calvani N, Marino A, Orlando L, Schiavone P, Quaranta A, Cinieri S.
    Crit Rev Oncol Hematol; 2012 Nov 10; 84(2):243-51. PubMed ID: 22494933
    [Abstract] [Full Text] [Related]

  • 20. Current and future anti-HER2 therapy in breast cancer.
    Vrbic S, Pejcic I, Filipovic S, Kocic B, Vrbic M.
    J BUON; 2013 Nov 10; 18(1):4-16. PubMed ID: 23613383
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 34.